PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: RNCOS E-Services (P) Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Russian Pharmaceutical Sector Exhibiting Strong Performance Reports RNCOS - Backed by government support and private sector investment, the Russian pharmaceutical market is likely to grow at a CAGR of 13% during 2011-2013, says RNCOS
Russian Pharmaceutical Sector Exhibiting Strong Performance Reports RNCOS

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2012/02/09 - Backed by government support and private sector investment, the Russian pharmaceutical market is likely to grow at a CAGR of 13% during 2011-2013, says RNCOS.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

According to our new research report,“Russian Pharma Sector Forecast to 2013”, the Russian pharmaceutical industry has been witnessing stupendous growth during the last few years. Government support and other key factors have led to create a US$ 18.09 Billion worth Russian pharmaceutical market in 2010. In the coming future also, it is foreseen that there will be a noteworthy growth in the private sector investments with the tremendous effort of the government towards promoting the local manufacture of drugs. On the basis of the existing circumstances, the market is estimated to grow at a CAGR of around 13% amounting to around US$ 25.68 Billion by the end of the forecast period (2011-2013).

It has also been found that the Rx or prescription drugs experienced faster growth compared to the OTC drugs in the past. Rx drugs not only grew by 0.7 percentage points in 2009, but also occupied a higher market share in terms of Rubles’ value due to their price value against the OTC drugs. The share of OTC drug is expected to further reduce as the drug affordability of people is improving, thereby enabling them to go for patented drugs.

The report provides precise and reliable information supplemented by relevant statistics of the Russian pharma sector. It seeks to explore the growth opportunities of the Russian pharmaceutical market and provides reliable figures of the key segments. It also presents an in-depth insight of the commercial drug market and parapharmaceuticals along with a brief overview of the key industry players to provide a balanced research outlook of the market.

While compiling the data, the report covered a brief outlook on the clinical trials market in order to provide a snapshot of the research domain. Forecasts in key sections of the report make use of proper base and techniques that provides a realistic future picture. Overall, the report is intended to present clients with an optimum source of knowledge and statistics on the concerned industry.

Report/IM243

About RNCOS
RNCOS (rncos.com) specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: RNCOS E-Services (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Russian Pharmaceutical Sector Exhibiting Strong Performance Reports RNCOS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Shushmul Maheshwari - RNCOS.com 
+91 12 04224700 press[.]rncos.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any RNCOS E-Services (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From RNCOS E-Services (P) Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)